title: Central pharmacological activity of a new piperazine derivative: 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester.
abstract: OBJECTIVE
  Our study focuses on the design and synthesis of a new piperazinic derivate, 4-(1-phenyl-1h-Pyrazol-4-Ylmethyl)-Piperazine-1-Carboxylic Acid Ethyl ester (LQFM008), and evaluation of its anxiolytic-like profile in Swiss mice.
  
  
  METHODS
  LQFM008 was evaluated in a screening test of the central nervous system including the rota-rod, sodium pentobarbital-induced sleep, open field, elevated plus maze and light-dark box tests.
  
  
  RESULTS
  LQFM008 induced convulsions at the dose of 1.1 mmol/kg (i.p., s.c. or p.o.). LQFM008 up to 400 μmol/kg had no effect in the rota rod test. In the open field test, LQFM008 increased the number of crossings and the time spent at the central area as well as the sleeping time in sodium pentobarbital-induced sleep. In the elevated plus maze and light-dark box tests, this compound showed an anxiolytic-like activity. This anxiolytic-like activity was antagonized by NAN-190 (5-HT(1A) antagonist) but not by flumazenil (benzodiazepine antagonist).
  
  
  CONCLUSIONS
  The compound LQFM008 showed anxiolytic-like activity which may involve serotonergic pathway.
authors.affiliation: Department of Physiologic Sciences, ICB, Federal University of Goiás, Campus Samambaia, 74001-970, 314, Goiânia, GO, Brazil.
authors.forename: Adriane Ferreira
authors.initials: AF
authors.lastname: de Brito
authors.forename: José Luís Rodrigues
authors.initials: JL
authors.lastname: Martins
authors.forename: James Oluwagbamigbe
authors.initials: JO
authors.lastname: Fajemiroye
authors.forename: Pablinny Moreira
authors.initials: PM
authors.lastname: Galdino
authors.forename: Thereza Christina Monteiro
authors.initials: TC
authors.lastname: De Lima
authors.forename: Ricardo
authors.initials: R
authors.lastname: Menegatti
authors.forename: Elson Alves
authors.initials: EA
authors.lastname: Costa
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005442:Flumazenil / Q000494:pharmacology; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D051379:Mice; D010424:Pentobarbital / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology*; D012701:Serotonin / Q000378:metabolism; D012890:Sleep / Q000187:drug effects; D013997:Time Factors
chemical_list: C574301:4-(1-phenyl-1H-pyrazol-4-ylmethyl)piperazine-1-carboxylic acid ethyl ester; D014151:Anti-Anxiety Agents; D010879:Piperazines; D011720:Pyrazoles; C058895:1-(2-methoxyphenyl)-4-(4-(2-phthalimido)butyl)piperazine; D012701:Serotonin; D005442:Flumazenil; D010424:Pentobarbital